The role of adaptive planning in margin-reduced, MRI-guided stereotactic body radiotherapy to the prostate bed following radical prostatectomy: Post-hoc analysis of a phase II clinical trial

被引:9
作者
Nikitas, John [1 ]
Smith, Lauren M. [1 ]
Gao, Yu [1 ]
Ma, Ting Martin [1 ]
Sachdeva, Ankush [1 ]
Yoon, Stephanie M. [1 ]
Jiang, Tommy [1 ]
Low, Daniel A. [1 ]
Ballas, Leslie K. [2 ]
Steinberg, Michael L. [1 ]
Cao, Minsong [1 ]
Kishan, Amar U. [1 ,3 ]
机构
[1] Univ Calif Los Angeles, Dept Radiat Oncol, 200 Med Plaza,Ste B265, Los Angeles, CA 90025 USA
[2] Univ Southern Calif, Dept Radiat Oncol, 1441 Eastlake Ave, Los Angeles, CA 90033 USA
[3] 200 Med Plaza,Ste B265, Los Angeles, CA 90095 USA
关键词
Post-prostatectomy; Prostate cancer; Stereotactic body radiotherapy; MR-guided radiotherapy; Adaptive radiotherapy; RADIATION-THERAPY SMART; CANCER CONTROL; TARGET VOLUME; RECURRENCE;
D O I
10.1016/j.radonc.2023.109631
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: We examined the interfractional variations of clinical target volumes (CTVs), planning target volumes (PTVs), and organs-at-risk (OARs) in patients receiving MRI-guided stereotactic body radiotherapy (SBRT) to the prostate bed and evaluated the potential role of adaptive planning. Materials and Methods: 31 patients received 30-34 Gy in five fractions to the prostate bed on a phase II clinical trial. OARs, CTVs, and PTVs were retrospectively contoured on daily pretreatment MRIs (n = 155). Geometric comparisons were made between initial planning contours and daily pretreatment contours. Predicted treatment plans for each fraction were evaluated using the following constraints: CTV V95% >93%, PTV V95%>90%, bladder Dmax < 36.7 Gy, bladder V32.5 Gy < 35%, rectum Dmax < 36.7 Gy, rectum V27.5 Gy < 45%, rectum 32.5 Gy < 30%, and rectal wall V24Gy < 50%. Adaptive planning was simulated for all fractions that failed to meet these criteria. Plans were then re-evaluated. Results: Median change in volume was 0.48% for CTV,-24.5% for bladder, and 6.95% for rectum. Median DSC was 0.89 for CTV, 0.79 for bladder, and 0.76 for rectum. 145/155 fractions (93.5%) met CTV V95% >93%. 75/155 fractions (48.4%) failed at least one OAR dose constraint. Overall, 83/155 fractions (53.5%) met criteria for adapting planning. This affected 24/31 patients (77.4%). Following adaptive plan-ning, all fractions met CTV V95%>93% and PTV V95%>90% and 120/155 fractions (77.4%) met all OAR con-straints. Conclusion: Due to significant interfractional variations in anatomy, a majority of fractions failed to meet both target volume and OAR constraints. However, adaptive planning was effective in overcoming these anatomic changes. Adaptive planning should be routinely considered in prostate bed SBRT.(c) 2023 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 185 (2023) 109631
引用
收藏
页数:8
相关论文
共 29 条
  • [1] Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued rise of biochemical failure after 5 years
    Amling, CL
    Blute, ML
    Bergstralh, EJ
    Seay, TM
    Slezak, J
    Zincke, H
    [J]. JOURNAL OF UROLOGY, 2000, 164 (01) : 101 - 105
  • [2] Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy
    Ballas, Leslie K.
    Luo, Chunqiao
    Chung, Eugene
    Kishan, Amar U.
    Shuryak, Igor
    Quinn, David I.
    Dorff, Tanya
    Jhimlee, Shamim
    Chiu, Raymond
    Abreu, Andre
    Jennelle, Richard
    Aron, Monish
    Groshen, Susan
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (01): : 50 - 60
  • [3] Intra-fraction displacement of the prostate bed during post-prostatectomy radiotherapy
    Bell, Linda J.
    Eade, Thomas
    Hruby, George
    Bromley, Regina
    Kneebone, Andrew
    [J]. RADIATION ONCOLOGY, 2021, 16 (01)
  • [4] Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function ("trifecta")
    Bianco, FJ
    Scardino, PT
    Eastham, JA
    [J]. UROLOGY, 2005, 66 (5A) : 83 - 94
  • [5] Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
    Brand, Douglas H.
    Tree, Alison C.
    Ostler, Peter
    van der Voet, Hans
    Loblaw, Andrew
    Chu, William
    Ford, Daniel
    Tolan, Shaun
    Jain, Suneil
    Martin, Alexander
    Staffurth, John
    Camilleri, Philip
    Kancherla, Kiran
    Frew, John
    Chan, Andrew
    Dayes, Ian S.
    Henderson, Daniel
    Brown, Stephanie
    Cruickshank, Clare
    Burnett, Stephanie
    Duffton, Aileen
    Griffin, Clare
    Hinder, Victoria
    Morrison, Kirsty
    Naismith, Olivia
    Hall, Emma
    van As, Nicholas
    [J]. LANCET ONCOLOGY, 2019, 20 (11) : 1531 - 1543
  • [6] Interfractional Geometric Variations and Dosimetric Benefits of Stereotactic MRI Guided Online Adaptive Radiotherapy (SMART) of Prostate Bed after Radical Prostatectomy: Post-Hoc Analysis of a Phase II Trial
    Cao, Minsong
    Gao, Yu
    Yoon, Stephanie M.
    Yang, Yingli
    Sheng, Ke
    Ballas, Leslie K.
    Basehart, Vincent
    Sachdeva, Ankush
    Felix, Carol
    Low, Daniel A.
    Steinberg, Michael L.
    Kishan, Amar U.
    [J]. CANCERS, 2021, 13 (11)
  • [7] CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed
    Detti, B.
    Bonomo, P.
    Masi, L.
    Doro, R.
    Cipressi, S.
    Iermano, C.
    Bonucci, I.
    Franceschini, D.
    Di Brina, L.
    Baki, M.
    Simontacchi, G.
    Meattini, I.
    Carini, M.
    Serni, S.
    Nicita, G.
    Livi, L.
    [J]. WORLD JOURNAL OF UROLOGY, 2016, 34 (03) : 311 - 317
  • [8] Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review
    Foerster, Robert
    Zwahlen, Daniel Rudolf
    Buchali, Andre
    Tang, Hongjian
    Schroeder, Christina
    Windisch, Paul
    Vu, Erwin
    Akbaba, Sati
    Bostel, Tilman
    Sprave, Tanja
    Zamboglou, Constantinos
    Zilli, Thomas
    Stelmes, Jean-Jacques
    Telkhade, Tejshri
    Murthy, Vedang
    [J]. CANCERS, 2021, 13 (04) : 1 - 17
  • [9] Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series
    Francolini, Giulio
    Jereczek-Fossa, Barbara Alicja
    Di Cataldo, Vanessa
    Simontacchi, Gabriele
    Marvaso, Giulia
    Zerella, Maria Alessia
    Gentile, Piercarlo
    Bianciardi, Federico
    Allegretta, Sara
    Detti, Beatrice
    Masi, Laura
    lo Russo, Monica
    Livi, Lorenzo
    [J]. BJU INTERNATIONAL, 2020, 125 (03) : 417 - 425
  • [10] Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer
    Han, M
    Partin, AW
    Zahurak, M
    Piantadosi, S
    Epstein, JI
    Walsh, PC
    [J]. JOURNAL OF UROLOGY, 2003, 169 (02) : 517 - 523